Podcast: Margaret E. O'Kane Discusses Her Pioneering Work on Quality Measurement

The executive order targets lower drug prices through Medicare reforms, anticompetitive crackdowns, and transparency mandates.

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

The California-based entities plan to offer new Medicare Advantage (MA) products in select counties by this fall.

A group of experts discusses the use of continuous glucose monitoring (CGM) technology in diabetes and its transformative potential in managing the disease.

A new technology for management of diabetes is cost-effective for patients in the US with type 1 diabetes compared with traditional treatments.

Taxing imports to the US could spell major consequences for health care prices, innovation, and access, as a great amount of medical supplies and ingredients are manufactured overseas.